The first patient was diagnosed with CTRC-NTRK1 fusion-positive pancreatic cancer and developed off-target resistance after 5 months of larotrectinib therapy, acquiring BRAFV600E and KRASG12D mutations through paired sequencing. This evidence concerns the gene NTRK1 and pancreatic neoplasm.